This is a combined antibody and antigen test holds considerable promise for HIV screening and has been approved in Europe since 2004. It is not a test to be used for screening blood. We are six years later coming to the table on this test.
The test will help doctors diagnose acute or primary HIV-1 infection, and to diagnose HIV-1/HIV-2 infection in pregnant women. BD
Every nine and a half minutes, someone in the United States is infected with HIV, and one out of every five of these individuals doesn’t know it. To help stem the spread of this disease, the U.S. Food and Drug Administration (FDA) today approved an innovative new diagnostic tool, which will allow patients to be diagnosed earlier than ever before.
Abbott’s ARCHITECT HIV Ag/Ab Combo assay is the first test approved in the United States that can simultaneously detect both HIV antigen and antibodies. HIV antigen is a protein produced by the virus immediately after infection, whereas antibodies are developed days later as the body works to fight off the infection. Studies have demonstrated that Abbott’s new test may detect HIV days earlier than antibody-only tests, which is important in controlling the spread of the virus.
This new test will run on Abbott’s ARCHITECT family of diagnostic testing instruments. It is already approved for use outside the United States. In Europe, HIV antigen-antibody combination testing is routine in public health settings and HIV testing guidelines in the United Kingdom now direct clinicians to use the HIV combination test as the first-line test.
FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests | BreakThrough Digest Medical News
0 comments :
Post a Comment